Blue Jet Healthcare ramps up with ₹23 billion for Andhra Pradesh Pharmaceutical Plant
Published: 11 Mar 2026
Author: Precedence Research
The establishment of a ₹23 billion greenfield pharmaceutical manufacturing facility by Blue Jet Healthcare Limited in Rambilli Industrial Park, Anakapalli, is expected to significantly enhance India's manufacturing capacity for CDMOs and specialty pharmaceuticals.
The 102-acre project aims to produce contrast media key intermediates, high-intensity sweeteners, and versatile chemical products, thereby expanding the company's presence in specialty chemicals and contract development and manufacturing services. The facility will be developed in phases and is expected to be operational by FY 2028-29.
In addition to increasing manufacturing capacity, the project is expected to generate about 1,750 direct jobs and 250 indirect employment opportunities, strengthening the Visakhapatnam region's industrial and pharmaceutical ecosystem.
According to Precedence Research, the Contrast Media Market was valued at USD 7.35 billion in 2025 and is projected to grow from USD 7.97 billion in 2026 to approximately USD 16.54 billion by 2035, expanding at a CAGR of 8.45% from 2026 to 2035, driven by healthcare awareness, rapid technological advancements, and the growing prevalence of chronic diseases.
Expanding specialty intermediates and CDMO capabilities
Originally established in 1968 as jet chemical, Pvt Ltd, Blue Jet Healthcare has grown into an integrated CDMO supplying advanced pharmaceutical intermediates and Apis to market. Across India, Europe and the United States. The company has emerged as a notable player in the contrast media intermediate, and was also among the early manufacturers of saccharin in India,
Over the decades, Bluejet has strengthened its chemistry process, experts scale up capabilities and regulatory complaint manufacturing infrastructure. The Ramabilli investment reflects the company’s strategy to expand its global CDMO footprint and support multinational pharmaceutical companies seeking diversified and resilient supply chains beyond single geographies.
Pioneering ESG-Focused Pharmaceutical Production
The new facility incorporates zero liquid discharge technology and an advanced effluent treatment plant, connecting to marine discharge. It intends to reduce energy consumption by approximately 70% and recover 90-95% of wastewater, aligning with stringent ESG benchmarks and environmental regulations in the pharmaceutical sector.
Led by Chairman Akshay Bansarilal Arora and MD Shiven Akshay Arora, the company's expansion underscores its dedication to sustainable pharmaceutical production, enhancing Rambilli Industrial Park’s position in India’s specialty chemicals hub and reflecting ongoing investments in complex intermediates as India advances in the global pharmaceutical value chain.
A recent report by Precedence Research highlights that the Contrast Media Market is benefiting from advancements in contrast media infrastructure.